ClinicalTrials.gg
Not yet recruitingNCT07509762Updated Jun 17, 2026

Exercise Programs in Women With PCOS

An interventional study of Face-to-face exercise and Digital rehabilitation in Polycystic Ovarian Syndrome (PCOS), sponsored by Biruni University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Biruni University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Polycystic Ovary Syndrome with a site in Turkey — 14 open to participants now, 15 under way, none of them phase 3. Polycystic Ovary Syndrome · Turkey.

Planned enrollment
22nd of 29
33 · median 54
Started
2026
with 11 others
No phase
26 of 72
9 open now
Primary completion
2027-01
later than 9 of 14 live
Registered
62nd of 72
by date

Among the 72 studies in Polycystic Ovary Syndrome with a site in Turkey, this one is the 22nd largest by planned enrollment of the 29 interventional ones that give a count, is one of 12 that started in 2026, is one of 26 with no phase, reaches primary completion later than 9 of the 14 other live ones, and was the 62nd registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

14 of the 72 studies in Polycystic Ovary Syndrome with a site in Turkey are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Polycystic Ovary Syndrome with a site in Turkey, or all of them as a file.
02

Study summary

This study aims to investigate the effectiveness of a digital rehabilitation-supported combined exercise program in women with Polycystic Ovary Syndrome (PCOS). Participants aged 18-40 years will be randomly assigned to one of three groups: a digital rehabilitation group, a face-to-face exercise group, and a physical activity counseling group. The intervention will last 8 weeks, with exercise performed three times per week. Outcomes will include DNA methylation, hormonal and metabolic parameters, anthropometric measurements, body composition, muscle strength, basal metabolic rate, physical activity level, quality of life, menstrual cycle regularity, exercise adherence and satisfaction.

Read the detailed description

Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder associated with metabolic, hormonal, and reproductive dysfunctions. Exercise is a key component in the management of PCOS; however, adherence to exercise programs remains a major challenge.

This randomized controlled trial aims to evaluate the effectiveness of a digital rehabilitation-supported combined exercise program compared to face-to-face supervised exercise and physical activity counseling.

Participants aged 18-40 years will be randomly assigned into three groups:

  1. Face-to-face exercise group
  2. Digital rehabilitation group
  3. Physical activity counseling group The intervention will last for 8 weeks, with exercise sessions conducted three times per week.

The face-to-face group will participate in supervised exercise sessions conducted by physiotherapist. The digital rehabilitation group will perform the same exercise protocol as the face-to-face group group online, live (synchronously), under the guidance of physiotherapist. The counseling group will receive physical activity recommendations.

Outcome measures will include epigenetic changes (DNA methylation), hormonal and metabolic parameters, anthropometric measurements, body composition, muscle strength, basal metabolic rate, physical activity level, quality of life, menstrual cycle regularity, exercise adherence and satisfaction.

03

Conditions studied

  • Polycystic Ovarian Syndrome (PCOS)

Keywords

  • PCOS, Digital rehabilitation, combined exercise, DNA methylation
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18-40 years diagnosed with PCOS according to the Rotterdam criteria (Rotterdam, 2003) and by a specialist physician.

The presence of at least two of the following three criteria will be considered sufficient for a diagnosis of PCOS according to the Rotterdam criteria: (i) history of irregular menstruation with oligo/anovulation, (ii) clinical and/or biochemical signs of hyperandrogenism, (iii) detection of polycystic ovary images on ultrasonography.

  • Having sufficient technological skills to participate in the treatment online (ability to use video conferencing applications)
  • Voluntary participation in the study

Exclusion criteria

Exclusion Criteria:

  • Pregnant and breastfeeding women
  • Individuals with acute infections
  • Uncontrolled arrhythmia, hypertension, diabetes, and unstable angina pectoris
  • Impaired cooperation, orthopedic and neurological problems that may hinder assessment and program participation
  • Individuals with a history of lower extremity injury or surgery in the last six months
  • Individuals with class III obesity according to WHO classification ( > 40 kg/m2) (WHO, 2000)
  • Individuals receiving medical treatment for weight loss (liraglutide, semaglutide, orlistat, bupropion/naltrexone, thizzpatide) or participating in a structured diet program during the study period
  • Individuals actively participating in another exercise program
  • Individuals taking antihypertensive, insulin-sensitizing, or hormonal drugs in the last 3 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    Face-to-face Exercise Group

    Participants will perform combined exercise sessions with a physiotherapist, three times per week for 8 weeks.

    Behavioral: Face-to-face exercise

  • Experimental
    Digital Rehabilitation Group

    Participants will perform a combined exercise program by digital rehabilitation tools with physiotherapist, three times per week for 8 weeks.

    Behavioral: Digital rehabilitation

  • No intervention
    Physical Activity Counseling Group

    Participants will receive physical activity recommendations.

Interventions

  • BehavioralFace-to-face exercise

    Participants will perform the same combined exercise program (aerobic and resistance exercises) delivered in person by the study team. Sessions are supervised directly in a clinical setting.

  • BehavioralDigital rehabilitation

    Participants will perform a combined exercise program (aerobic and resistance exercises) through a digital rehabilitation platform.

06

What researchers measure

Primary outcomes

  1. Change in DNA methylation levels in women with PCOS

    Genome-wide DNA methylation analysis will be used to measure methylation in blood samples taken baseline and after 8 weeks.

    Time frame: Baseline and after 8 week

Secondary outcomes

  1. Hormonal Parameter Testosterone

    Serum levels of testosterone will be measured at baseline and after 8 weeks.

    Time frame: Baseline and after 8 weeks.

  2. Hormonal Parameter Luteinizing Hormone

    Serum levels of luteinizing hormone (LH) will be measured at baseline and after 8 weeks.

    Time frame: Baseline and after 8 weeks

  3. Hormonal Parameter Follicle-Stimulating Hormone

    Serum levels of follicle-stimulating hormone (FSH) will be measured at baseline and after 8 weeks.

    Time frame: Baseline and after 8 weeks

  4. Metabolic Parameter Fasting Blood Glucose

    For the evaluation of fasting blood glucose (FPG) will be measured in all participants baseline and after 8 weeks.

    Time frame: Baseline and after 8 weeks

  5. Metabolic Parameter Insulin Level

    For the evaluation of insulin level will be measured in all participants baseline and after 8 weeks.

    Time frame: Baseline and after 8 weeks

  6. Metabolic Parameter High-Density Lipoprotein Cholesterol

    For the evaluation of high-density lipoprotein cholesterol (HDL-C) will be measured in all participants baseline and after 8 weeks.

    Time frame: Baseline and after 8 weeks

  7. Metabolic Parameter Low-Density Lipoprotein Cholesterol

    For the evaluation of low-density lipoprotein cholesterol (LDL-C) will be measured in all participants baseline and after 8 weeks.

    Time frame: Baseline and after 8 weeks

  8. Metabolic Parameter Total Cholesterol

    For the evaluation of total cholesterol will be measured in all participants baseline and after 8 weeks.

    Time frame: Baseline and after 8 weeks

  9. Metabolic Parameter Triglycerides

    For the evaluation of triglycerides will be measured in all participants baseline and after 8 weeks.

    Time frame: Baseline and after 8 weeks

  10. Metabolic Parameter C-Reactive Protein

    For the evaluation of C-reactive protein (CRP) will be measured in all participants baseline and after 8 weeks.

    Time frame: Baseline and after 8 weeks

  11. Anthropometric Measurements Waist Circumference

    Waist circumference will be measured using standardized tape.

    Time frame: Baseline and after 8 weeks

  12. Anthropometric Measurements Hip Circumference

    Hip circumference will be measured using standardized tape.

    Time frame: Baseline and after 8 weeks

  13. Body Composition Body Mass Index

    Participants' BMI will be measured using Bioelectrical Impedance Analysis (BIA).

    Time frame: Baseline and after 8 weeks

  14. Body Composition Body Fat Mass

    Participants' body fat mass (kg) will be measured using Bioelectrical Impedance Analysis (BIA).

    Time frame: Baseline and after 8 weeks

  15. Body Composition Body Fat Percentage

    Participants' body fat percentage (%) will be measured using Bioelectrical Impedance Analysis (BIA).

    Time frame: Baseline and after 8 weeks

  16. Body Composition Body Muscle Percentage

    Participants' body muscle percentage (%) will be measured using Bioelectrical Impedance Analysis (BIA).

    Time frame: Baseline and after 8 weeks

  17. Body Composition Body Muscle Mass

    Participants' body muscle mass (kg) will be measured using Bioelectrical Impedance Analysis (BIA).

    Time frame: Baseline and after 8 weeks

  18. Body Composition Lean Body Mass

    Participants' lean body mass (kg) will be measured using Bioelectrical Impedance Analysis (BIA).

    Time frame: Baseine and after 8 weeks

  19. Body Composition Visceral Fat

    Participants' visceral fat will be measured using Bioelectrical Impedance Analysis (BIA).

    Time frame: Baseline and after 8 weeks

  20. Basal Metabolic Rate

    Basal metabolic rate measurements will be taken using a portable indirect calorimeter.

    Time frame: Baseline and 8 weeks

  21. Peripheral Muscle Strength

    Peripheral muscle strength assessment will include measurements of quadriceps femoris muscle strength and hand grip strength. An electronic hand dynamometer will be used to assess quadriceps femoris muscle strength. Participants' grip strength will be measured using a Jamar brand hydraulic hand dynamometer.

    Time frame: Baseline and 8 weeks

  22. Physical Activity Level

    Physical activity level will be measured with a wearable activity monitor that tracks daily step count and activity minutes.

    Time frame: Baseline and after 8 weeeks

  23. Change in Quality of Life Score

    The Turkish version of the Polycystic Ovary Syndrome (PCOS) Quality of Life-50 Questionnaire (PCOSQ-50) will be used to assess quality of life. The scale's total score and subscale scores are calculated using a scale with values of never 5, rarely 4, sometimes 3, frequently 4, and always 1. The total score ranges from 50 to 250 points.

    Time frame: Baseline and after 8 weeks.

  24. Change in Menstrual Cycle Regularity

    Changes in menstrual cycle regularity will be assessed at baseline and after 8 weeks using daily logs.

    Time frame: Baseline and after 8 weeks

  25. Exercise Adherence

    Participants' attendance and compliance with the sessions will be directly monitored by the physiotherapist. Attendance will be determined based on the number of sessions attended, for a total of 24 sessions. Attendance is defined as attending at least 80% of the scheduled exercise sessions.

    Time frame: Baseline and after 8 weeks

  26. Exercise Satisfaction

    Participants' satisfaction level with the exercise programs will be assessed using the Global Rating of Change (GRC). Participants will be asked to express their level of satisfaction with the application using a single question. They will be asked to rate their satisfaction on a 5-point Likert scale, with "1" representing very poor satisfaction and "5" representing very good satisfaction.

    Time frame: Baseline and after 8 weeks

07

Study locations

1 site
  • Biruni University
    Istanbul, 34015, Turkey (Türkiye)
    • Buket Akıncı, Prof. Dr. · Contactbakinci@biruni.edu.tr · +90 505 641 5692
    • Kübra Arslan · Contactkbra.arslan96@gmail.com · +90 543 947 0584
    • Buket Akıncı, Prof. Dr. · Principal investigator
    • Kübra Arslan · Sub investigator
    • Volkan Turan, Prof. Dr. · Sub investigator
    • Tuğba Elgün, PhD · Sub investigator
    • Şafak Yiğit, PhD · Sub investigator
08

References and documents

Publications

  • Turan V, Mutlu EK, Solmaz U, Ekin A, Tosun O, Tosun G, Mat E, Gezer C, Malkoc M. Benefits of short-term structured exercise in non-overweight women with polycystic ovary syndrome: a prospective randomized controlled study. J Phys Ther Sci. 2015 Jul;27(7):2293-7. doi: 10.1589/jpts.27.2293. Epub 2015 Jul 22. PubMed 26311969 ↗
  • Wright PJ, Burts C, Harmon C, Corbett CF. Availability and Use of Digital Technology Among Women With Polycystic Ovary Syndrome: Scoping Review. JMIR Infodemiology. 2025 Jun 12;5:e68469. doi: 10.2196/68469. PubMed 40505084 ↗

Related links

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared due to privacy concerns and institutional regulations at Biruni University.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jan 2027, 4 months later.

Of 205 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 4 months is below that.

Counting every sponsor, half of 220 studies reached it within 17 months; a quarter within 7 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Apr 3, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Jan 15, 2027
CompletionEst.
Mar 25, 2027
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07509762
Lead sponsor
Biruni University
Responsible party
Buket AKINCI (Prof. Dr., Biruni University) — Principal investigator
First posted
Apr 3, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Jan 15, 2027 (estimated)
Completion
Mar 25, 2027 (estimated)
Last update
Jun 17, 2026

Study contacts

Buket Akinci, Prof. Dr.
Contact
bakinci@biruni.edu.tr
+905056415692
Kübra Arslan, MsC
Contact
kbra.arslan96@gmail.com
+905439470584
Buket Akıncı, Prof. Dr.
principal investigator · Biruni University, Faculty of Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion